TLR13 Inhibitors
Chemical inhibitors of Toll-like receptor 13 (TLR13) function through various mechanisms to disrupt the normal signaling pathway of this innate immune receptor. Chloroquine, Quinacrine, and Hydroxychloroquine operate by increasing the pH within endosomes. This elevation in pH impairs the endosome's maturation process, which is a critical step for TLR13 to recognize its RNA ligands. Without proper recognition, the signaling cascade that typically follows ligand binding is interrupted. The lysosomotropic agent Ammonium Chloride similarly raises endosomal pH, leading to a comparable inhibitory effect on TLR13 signaling. Monensin, an ionophore, disrupts pH gradients by altering the ionic balance necessary for endosomal acidification, indirectly inhibiting the recognition process essential for TLR13 activation.
On the other hand, Bafilomycin A1 and Concanamycin A target the vacuolar-type H+-ATPase (V-ATPase), a proton pump that acidifies endosomes. By inhibiting V-ATPase, these compounds prevent the endosome from reaching the acidic pH required for TLR13 to detect its ligands. E-64 and Z-VAD-FMK, both protease inhibitors, interfere with the proteolytic processing within endosomes. This processing is often a prerequisite for the proper presentation and recognition of ligands by TLR13. Pepstatin A, an aspartic protease inhibitor, also disrupts this critical proteolytic activity within the endosome. Nystatin affects endosomal membrane integrity, which can interfere with ligand recognition by TLR13. Lastly, U18666A changes the endosomal membrane composition by inhibiting cholesterol transport, which can disrupt the membrane environment necessary for TLR13-mediated signaling. Each of these chemicals, by affecting the endosomal environment or the processes within, can interrupt the activity of TLR13, halting the receptor's ability to signal effectively upon ligand recognition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an antimalarial drug that can inhibit the endosomal acidification, which is crucial for the TLR13 signaling as TLR13 recognizes single-stranded RNA in endosomes. By increasing the pH, Chloroquine disrupts endosomal maturation and therefore inhibits TLR13 signaling. | ||||||
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $46.00 $57.00 $87.00 $3257.00 $4821.00 | 4 | |
Quinacrine is another antimalarial compound that acts similarly to Chloroquine. It can raise the pH within endosomes and lysosomes, thereby inhibiting TLR13 activity by preventing the proper recognition of its RNA ligands within the endosome. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine functions like Chloroquine and Quinacrine by increasing the pH in endosomes and disrupting the maturation of these organelles, which is necessary for TLR13 activation by its ligands. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase) which is involved in the acidification of endosomes. Inhibition of V-ATPase by Bafilomycin A1 leads to a less acidic endosome and thus impairs TLR13 signaling. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, like Bafilomycin A1, is a V-ATPase inhibitor and thereby increases endosomal pH, which is necessary for TLR13 to recognize its ligand. This impairment of endosomal acidification inhibits TLR13 function. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor that can disrupt the proteolytic processing within endosomes, an essential step for certain ligands to be recognized by TLR13, leading to inhibition of TLR13 signaling. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can also affect the proteolytic processing within the endosome, potentially inhibiting TLR13 activity by preventing ligand recognition. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
Ammonium Chloride acts as a lysosomotropic agent that can elevate the pH of endosomes and lysosomes, thereby inhibiting TLR13 by preventing activation in response to its ligands within the normally acidic endosome. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts endosomal pH gradients. By altering the ionic balance required for endosomal acidification, Monensin inhibits TLR13 signaling by obstructing the ligand recognition in the endosome. | ||||||
Nystatin | 1400-61-9 | sc-212431 sc-212431A sc-212431B sc-212431C | 5 MU 25 MU 250 MU 5000 MU | $51.00 $129.00 $251.00 $3570.00 | 7 | |
Nystatin is an antifungal polyene that disrupts membrane integrity. While its primary action is on cell membranes, it can also affect endosomal membranes and thus potentially inhibit TLR13 signaling by disrupting endosomal ligand recognition. | ||||||